Humacyte Inc (HUMA)

$0.72 -0.01 (-1.15%)
Market Cap 171.15M
Revenue (ttm) 2.04M
Net Income (ttm) -40.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,001.47%
Debt to Equity Ratio 3.09
Volume 6,378,877
Avg Vol 11,535,448
Day's Range N/A - N/A
Shares Out 222.02M
Stochastic %K 47%
Beta 2.52
Analysts Strong Sell
Price Target $1.96

Company Profile

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 919 313 9633
Address:
2525 East North Carolina Highway 54, Durham, United States
izamgeoff
izamgeoff Jul. 9 at 4:45 PM
$HUMA Another big catalyst coming up next week. Been a while since being hit hard and oversold on good news + dilution (rearview mirror). Funded and derisked for dialysis application and waiting on news of new global partnerships
0 · Reply
Starwanderer
Starwanderer Jul. 9 at 4:42 PM
$HUMA One must remember that we are at sub-$1.50 only because of the capital raise that followed the stellar scientific results. People cry about dilution as it it were a black swan event, forgetting that not only it's normal for a pre-revenue company, especially a biotech, to fund its trials by raising capital from time to time, but that with biotechs good science, close product-approval milestones and TAM are the most valuable assets - and HUMA has them ALL. This is indeed free money at these levels.
0 · Reply
Timerider
Timerider Jul. 9 at 4:13 PM
$HUMA When they let her run the 1.33 gap will close in a hurry. Bigs in at 9 and over, dilution at 1.05 Lag time about over
1 · Reply
Abetwit
Abetwit Jul. 9 at 3:40 PM
$HUMA Picked up another 25k. I think I am too early but heck...
0 · Reply
Timerider
Timerider Jul. 9 at 3:10 PM
$HUMA Added 75k shares n .71 area this am .83 coming after this support retest
0 · Reply
Jtlo
Jtlo Jul. 9 at 2:23 PM
$HUMA in good luck
0 · Reply
Connor1111
Connor1111 Jul. 9 at 2:09 PM
$HUMA Added to my position at yesterday's close at .71, bringing my total up to 160k shares. Very bullish on their bioengineered tissue platform long term and planning to continue accumulating at these current price levels
2 · Reply
Abetwit
Abetwit Jul. 9 at 1:45 PM
$HUMA wtf?
0 · Reply
rubraquercus
rubraquercus Jul. 9 at 1:28 PM
$HUMA My spider senses tell me the next news will be a cash deal for ex-usa distribution/sales of their bioengineered blood vessel for hemodialysis... The 2026 Amendment: In April 2026, Humacyte and Fresenius Medical Care amended their distribution agreement. Humacyte regained exclusive global rights for the product outside the U.S., allowing them to pursue independent commercialization in countries like Israel and Saudi Arabia. Fresenius' Role: Fresenius receives a low-single-digit royalty on ex-U.S. net sales and continues to support the product's clinical progress. U.S. distribution terms remain unchanged.
1 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Jul. 9 at 1:24 PM
🌅📈 Watchlist part 2 ✅ $SUNE 2.40 support, if above 2.50, have potential to 2.70/2.80. Recent 13G filing shows AWM Investment with a 19.9% stake. ✅ $IOTR 3.80 support, if above 4, have potential to 4.50/4.70 ✅ $PCLA Low 4 support, if above 4.70, have potential to 5/5.50 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $CHAI $HUMA still in swing accumulation phase 🎯🎯 Goal is GREEN 🤑🤑 not GREED 🥵🥵
0 · Reply
Latest News on HUMA
Humacyte price target lowered to $1.25 from $1.50 at TD Cowen

2026-06-17T12:32:32.000Z - 22 days ago

Humacyte price target lowered to $1.25 from $1.50 at TD Cowen

Humacyte Slides: Corporate presentation

Jun 16, 2026, 3:00 PM EDT - 22 days ago

Humacyte Slides: Corporate presentation

Humacyte Transcript: Study result

Jun 15, 2026, 5:00 PM EDT - 23 days ago

Humacyte Transcript: Study result

Humacyte Press release: Study result

Jun 15, 2026, 5:00 PM EDT - 23 days ago

Humacyte Press release: Study result

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

Jun 15, 2026, 8:00 AM EDT - 24 days ago

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

Humacyte price target raised to $4 from $3 at H.C. Wainwright

2026-06-11T13:47:07.000Z - 4 weeks ago

Humacyte price target raised to $4 from $3 at H.C. Wainwright

Humacyte 47.62M share Spot Secondary priced at $1.05

2026-06-11T01:35:07.000Z - 4 weeks ago

Humacyte 47.62M share Spot Secondary priced at $1.05

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Jun 10, 2026, 9:08 PM EDT - 4 weeks ago

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte TBA Spot Secondary; price range $1.05-$1.15

2026-06-10T22:15:08.000Z - 4 weeks ago

Humacyte TBA Spot Secondary; price range $1.05-$1.15

Humacyte announces V012 study of ATEV meets primary endpoint

2026-06-10T20:14:24.000Z - 4 weeks ago

Humacyte announces V012 study of ATEV meets primary endpoint

Humacyte announces common stock offering, no amount given

2026-06-10T20:10:11.000Z - 4 weeks ago

Humacyte announces common stock offering, no amount given

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Jun 10, 2026, 4:04 PM EDT - 4 weeks ago

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

Jun 10, 2026, 4:01 PM EDT - 4 weeks ago

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

Humacyte Transcript: AGM 2026

Jun 9, 2026, 8:00 AM EDT - 4 weeks ago

Humacyte Transcript: AGM 2026

Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Jun 5, 2026, 3:52 PM EDT - 4 weeks ago

Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Humacyte price target raised to $2 from $1 at Benchmark

2026-06-01T11:58:24.000Z - 5 weeks ago

Humacyte price target raised to $2 from $1 at Benchmark

Humacyte announces presentation at VASA meeting on self-repair ATEV

2026-05-26T15:23:12.000Z - 6 weeks ago

Humacyte announces presentation at VASA meeting on self-repair ATEV

Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access

May 26, 2026, 8:00 AM EDT - 6 weeks ago

Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access

Humacyte reports Symvess under contract with Strategic Acquisition Center of VA

2026-05-20T12:14:56.000Z - 7 weeks ago

Humacyte reports Symvess under contract with Strategic Acquisition Center of VA

Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs

May 20, 2026, 8:00 AM EDT - 7 weeks ago

Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs

Humacyte price target raised to $1.50 from $1 at TD Cowen

2026-05-14T15:08:47.000Z - 2 months ago

Humacyte price target raised to $1.50 from $1 at TD Cowen

Humacyte reports Q1 EPS (9c), consensus (12c)

2026-05-13T13:00:50.000Z - 2 months ago

Humacyte reports Q1 EPS (9c), consensus (12c)

Humacyte Earnings Call Transcript: Q1 2026

May 13, 2026, 8:00 AM EDT - 2 months ago

Humacyte Earnings Call Transcript: Q1 2026

Humacyte Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 2 months ago

Humacyte Earnings release: Q1 2026

Humacyte Quarterly report: Q1 2026

May 13, 2026, 8:00 AM EDT - 2 months ago

Humacyte Quarterly report: Q1 2026

Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update

May 13, 2026, 7:00 AM EDT - 2 months ago

Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update

Humacyte names Todd Rasmussen chief surgical officer

2026-05-12T15:32:56.000Z - 2 months ago

Humacyte names Todd Rasmussen chief surgical officer

Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer

May 12, 2026, 8:00 AM EDT - 2 months ago

Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

May 8, 2026, 6:00 PM EDT - 2 months ago

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

May 8, 2026, 8:00 AM EDT - 2 months ago

Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

Humacyte Transcript: KOL event

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Humacyte Transcript: KOL event

Humacyte Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Humacyte Proxy statement: Proxy filing

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

Humacyte realigns ex-U.S. rights to Symvess through Fresenius Medical pact

2026-04-24T12:33:04.000Z - 2 months ago

Humacyte realigns ex-U.S. rights to Symvess through Fresenius Medical pact

FMS

Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

Humacyte Appoints Jim Mercadante as Chief Commercial Officer

Apr 22, 2026, 8:00 AM EDT - 2 months ago

Humacyte Appoints Jim Mercadante as Chief Commercial Officer

Humacyte announces Israeli Ministry of Health acceptance of MAA for Symvess

2026-04-21T13:26:28.000Z - 2 months ago

Humacyte announces Israeli Ministry of Health acceptance of MAA for Symvess

Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair

Humacyte Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Humacyte Proxy statement: Proxy filing

Humacyte price target lowered to $1.50 from $3.50 at Barclays

2026-04-08T09:30:25.000Z - 3 months ago

Humacyte price target lowered to $1.50 from $3.50 at Barclays

Humacyte downgraded to Speculative Buy from Buy at Benchmark

2026-03-31T13:30:42.000Z - 3 months ago

Humacyte downgraded to Speculative Buy from Buy at Benchmark

Humacyte Earnings Call Transcript: Q4 2025

Mar 27, 2026, 8:00 AM EDT - 3 months ago

Humacyte Earnings Call Transcript: Q4 2025

Humacyte Annual report: Q4 2025

Mar 27, 2026, 8:00 AM EDT - 3 months ago

Humacyte Annual report: Q4 2025

Humacyte Earnings release: Q4 2025

Mar 27, 2026, 8:00 AM EDT - 3 months ago

Humacyte Earnings release: Q4 2025

Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Mar 27, 2026, 7:00 AM EDT - 3 months ago

Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Humacyte Appoints Rick McElheny as Senior Vice President of Business Development

Mar 26, 2026, 8:00 AM EDT - 3 months ago

Humacyte Appoints Rick McElheny as Senior Vice President of Business Development

Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026

Mar 23, 2026, 8:00 AM EDT - 3 months ago

Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026

Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock

Mar 19, 2026, 8:30 AM EDT - 4 months ago

Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock

Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair

Mar 17, 2026, 8:00 AM EDT - 4 months ago

Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair

Humacyte Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 1:00 PM EDT - 4 months ago

Humacyte Transcript: Barclays 28th Annual Global Healthcare Conference

Humacyte Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 10:30 AM EST - 4 months ago

Humacyte Transcript: TD Cowen 46th Annual Health Care Conference

Humacyte To Participate in Upcoming Investor Conferences

Mar 2, 2026, 8:00 AM EST - 4 months ago

Humacyte To Participate in Upcoming Investor Conferences

Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting

Feb 18, 2026, 8:00 AM EST - 5 months ago

Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting

Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

Feb 9, 2026, 8:00 AM EST - 5 months ago

Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications

Jan 8, 2026, 8:00 AM EST - 6 months ago

Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications

Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel

Jan 5, 2026, 8:00 AM EST - 6 months ago

Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel

Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

Dec 22, 2025, 8:00 AM EST - 7 months ago

Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital

Dec 16, 2025, 8:00 AM EST - 7 months ago

Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

Nov 20, 2025, 8:00 AM EST - 8 months ago

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

Nov 13, 2025, 8:00 AM EST - 8 months ago

Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

Humacyte Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Humacyte Earnings Call Transcript: Q3 2025

Humacyte Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Humacyte Quarterly report: Q3 2025

Humacyte Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Humacyte Earnings release: Q3 2025

Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 7:00 AM EST - 8 months ago

Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025

Nov 10, 2025, 8:00 AM EST - 8 months ago

Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Nov 6, 2025, 8:00 AM EST - 8 months ago

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma

Oct 30, 2025, 8:00 AM EDT - 9 months ago

Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

Oct 7, 2025, 9:00 AM EDT - 9 months ago

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

Oct 6, 2025, 8:00 AM EDT - 9 months ago

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus

Sep 29, 2025, 8:00 AM EDT - 10 months ago

Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

Sep 18, 2025, 7:00 AM EDT - 10 months ago

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

Sep 15, 2025, 7:00 AM EDT - 10 months ago

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

Humacyte Registration statement: Registration Filing

Sep 12, 2025, 8:00 AM EDT - 10 months ago

Humacyte Registration statement: Registration Filing

Humacyte Earnings Call Transcript: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Humacyte Earnings Call Transcript: Q2 2025

Humacyte Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Humacyte Quarterly report: Q2 2025

Humacyte Earnings release: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Humacyte Earnings release: Q2 2025

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Humacyte Announces First Symvess™ Sale to Military Treatment Facility

Jul 23, 2025, 8:00 AM EDT - 1 year ago

Humacyte Announces First Symvess™ Sale to Military Treatment Facility

Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency

Jul 8, 2025, 8:00 AM EDT - 1 year ago

Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency

Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

Humacyte Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 12:30 PM EDT - 1 year ago

Humacyte Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

May 19, 2025, 4:05 PM EDT - 1 year ago

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

Humacyte Earnings Call Transcript: Q1 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Humacyte Earnings Call Transcript: Q1 2025

Humacyte Quarterly report: Q1 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Humacyte Quarterly report: Q1 2025

Humacyte Earnings release: Q1 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Humacyte Earnings release: Q1 2025

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 7:30 AM EDT - 1 year ago

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

May 9, 2025, 8:00 AM EDT - 1 year ago

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

Humacyte Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Humacyte Proxy statement: Proxy Filing

Humacyte Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Humacyte Proxy statement: Proxy Filing

Humacyte Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Humacyte Proxy statement: Proxy Filing

Humacyte Earnings Call Transcript: Q4 2024

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Humacyte Earnings Call Transcript: Q4 2024

Humacyte Annual report: Q4 2024

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Humacyte Annual report: Q4 2024

Humacyte Earnings release: Q4 2024

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Humacyte Earnings release: Q4 2024

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Mar 28, 2025, 7:30 AM EDT - 1 year ago

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

izamgeoff
izamgeoff Jul. 9 at 4:45 PM
$HUMA Another big catalyst coming up next week. Been a while since being hit hard and oversold on good news + dilution (rearview mirror). Funded and derisked for dialysis application and waiting on news of new global partnerships
0 · Reply
Starwanderer
Starwanderer Jul. 9 at 4:42 PM
$HUMA One must remember that we are at sub-$1.50 only because of the capital raise that followed the stellar scientific results. People cry about dilution as it it were a black swan event, forgetting that not only it's normal for a pre-revenue company, especially a biotech, to fund its trials by raising capital from time to time, but that with biotechs good science, close product-approval milestones and TAM are the most valuable assets - and HUMA has them ALL. This is indeed free money at these levels.
0 · Reply
Timerider
Timerider Jul. 9 at 4:13 PM
$HUMA When they let her run the 1.33 gap will close in a hurry. Bigs in at 9 and over, dilution at 1.05 Lag time about over
1 · Reply
Abetwit
Abetwit Jul. 9 at 3:40 PM
$HUMA Picked up another 25k. I think I am too early but heck...
0 · Reply
Timerider
Timerider Jul. 9 at 3:10 PM
$HUMA Added 75k shares n .71 area this am .83 coming after this support retest
0 · Reply
Jtlo
Jtlo Jul. 9 at 2:23 PM
$HUMA in good luck
0 · Reply
Connor1111
Connor1111 Jul. 9 at 2:09 PM
$HUMA Added to my position at yesterday's close at .71, bringing my total up to 160k shares. Very bullish on their bioengineered tissue platform long term and planning to continue accumulating at these current price levels
2 · Reply
Abetwit
Abetwit Jul. 9 at 1:45 PM
$HUMA wtf?
0 · Reply
rubraquercus
rubraquercus Jul. 9 at 1:28 PM
$HUMA My spider senses tell me the next news will be a cash deal for ex-usa distribution/sales of their bioengineered blood vessel for hemodialysis... The 2026 Amendment: In April 2026, Humacyte and Fresenius Medical Care amended their distribution agreement. Humacyte regained exclusive global rights for the product outside the U.S., allowing them to pursue independent commercialization in countries like Israel and Saudi Arabia. Fresenius' Role: Fresenius receives a low-single-digit royalty on ex-U.S. net sales and continues to support the product's clinical progress. U.S. distribution terms remain unchanged.
1 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Jul. 9 at 1:24 PM
🌅📈 Watchlist part 2 ✅ $SUNE 2.40 support, if above 2.50, have potential to 2.70/2.80. Recent 13G filing shows AWM Investment with a 19.9% stake. ✅ $IOTR 3.80 support, if above 4, have potential to 4.50/4.70 ✅ $PCLA Low 4 support, if above 4.70, have potential to 5/5.50 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $CHAI $HUMA still in swing accumulation phase 🎯🎯 Goal is GREEN 🤑🤑 not GREED 🥵🥵
0 · Reply
Timerider
Timerider Jul. 9 at 11:32 AM
$HUMA Last minute selling yesterday should reset quickly after bell, same as .67 to .72 did. Susan should buy more soon
0 · Reply
Norap58
Norap58 Jul. 9 at 10:12 AM
$HUMA No,No,No the good folks who have run this firm as an alleged personal piggy bank and diluted the common shareholders 6x since 2024 and have less than 14 months COH now ALWAYS have the best interests of its shareholders at top of mind. Shut up shorty!
0 · Reply
Justlooking34
Justlooking34 Jul. 9 at 1:25 AM
$HUMA 💩
0 · Reply
1nceagain
1nceagain Jul. 9 at 1:21 AM
$HUMA
1 · Reply
izamgeoff
izamgeoff Jul. 9 at 1:00 AM
$HUMA so is the deadline for the Saudi entity to take the option to secure exclusive rights there passed?
2 · Reply
Timerider
Timerider Jul. 8 at 10:50 PM
$HUMA Lows .62 .67 .73 I wanted 100k at .72 Maybe tomorrow
1 · Reply
_Mazinger_Z
_Mazinger_Z Jul. 8 at 9:30 PM
$HUMA
0 · Reply
WallStreetPulse
WallStreetPulse Jul. 8 at 8:56 PM
$ZEUS led the 60m board +2.83%, with $MASK +2.6% and $EIGEN +2.46% showing steady bids. On the flip side, $ARG got hit hardest at -5.46%, while $HUMA fell -2.83% and $HMSTR stayed weak. Short-term momentum still favors the gainers, but the tape looks selective.
0 · Reply
Michael_Krombopulos
Michael_Krombopulos Jul. 8 at 8:14 PM
$HUMA they made sure the last minute rug pull was much harder this time. Doesn’t matter if it was only a minute drop of 7%. Their timing was perfect. Now the algos are gonna be convinced it’s in a downtrend because a lot of things only track close prices …and even if it holds tomorrow it will say you are up 7% … same manipulators, same Illegal coordination, new trading dynamic with the Russel institional ownership done. Out come the blatenly illegal tactics of the short firms. Next is a hit piece they authored through another branch of their criminal enterprise.
3 · Reply
SlvrShroud94
SlvrShroud94 Jul. 8 at 8:13 PM
$HUMA all these bears here and that drop before close, sounds like I need to buy more once my $SLS gets bought out. $IBRX too of course.
0 · Reply
realditzy
realditzy Jul. 8 at 8:02 PM
$HUMA
1 · Reply
izamgeoff
izamgeoff Jul. 8 at 8:01 PM
$HUMA crazy close. News?
0 · Reply